Keyphrases
Bone Lesions
100%
Prostate Cancer
100%
Effector Lymphocytes
100%
Adoptive Immunotherapy
100%
T-body
75%
Chimeric Antigen Receptor T Cells (CAR-T)
50%
Lymphocytes
25%
Surface Antigen
25%
Malignancy
25%
T Cells
25%
Tumor Growth
25%
Stromal Cell-derived factor-1 (SDF-1)
25%
ErbB2
25%
Receptor Gene
25%
Human Lymphocytes
25%
Natural Killer Cells
25%
Therapeutic Potential
25%
Therapeutic Efficacy
25%
Interleukin-2
25%
Effector Function
25%
SCID Mouse Model
25%
Effective Therapy
25%
High Specificity
25%
Androgen-independent
25%
Low-dose Cyclophosphamide
25%
Prostate-specific Antigen
25%
Androgen Ablation
25%
Low-dose Irradiation
25%
Medicine and Dentistry
Lymphocyte
100%
Prostate Cancer
100%
Adoptive Immunotherapy
100%
Bone Lesion
100%
Disease
50%
Androgen
50%
Conditioning
25%
Secretion (Process)
25%
Low Drug Dose
25%
Tumor Progression
25%
Combination Therapy
25%
Stromal Cell Derived Factor 1
25%
Cancer
25%
SCID Mouse
25%
Receptor Gene
25%
Natural Killer Cell
25%
Catheter Ablation
25%
Membrane Antigen
25%
T Lymphocyte
25%
Cyclophosphamide
25%
Prostate Specific Antigen
25%
Immunology and Microbiology
Lymphocyte
100%
Adoptive Immunotherapy
100%
Monospecific Antibody
33%
Mouse Model
33%
Mouse
33%
Secretion (Process)
33%
Membrane Antigen
33%
T Cell
33%
Receptor Gene
33%
Stromal Cell-Derived Factor 1
33%
Conditioning
33%
SCID Mouse
33%
Low Drug Dose
33%
Natural Killer Cell
33%
Prostate
33%
Cyclophosphamide
33%
Preclinical Study
33%
Prostate Specific Antigen
33%
Pharmacology, Toxicology and Pharmaceutical Science
Prostate Cancer
100%
Immunotherapy
100%
Bone Lesion
100%
Disease
50%
Androgen
50%
Mouse
25%
Receptor
25%
Mouse Model
25%
Tumor Growth
25%
Combination Therapy
25%
Stromal Cell Derived Factor 1
25%
Cyclophosphamide
25%
Membrane Antigen
25%
SCID Mouse
25%
Preclinical Study
25%
Prostate Specific Antigen
25%